Download PDF

1. Company Snapshot

1.a. Company Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally.The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software.


In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin.It has development and commercialization agreements with Dexcom, Inc.and Abbott Laboratories.


The company was formerly known as Phluid Inc.and changed its name to Tandem Diabetes Care, Inc.in January 2008.


Tandem Diabetes Care, Inc.was incorporated in 2006 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on TNDM

Tandem Diabetes Care, Inc. faced negative drivers, including allegations of issuing materially misleading business information, prompting investigations by Rosen Law Firm on behalf of shareholders. The company reported a Q4 loss of $0.01 per share, beating estimates, but concerns surrounding its business information and potential securities claims have raised uncertainty. Additionally, Tandem Diabetes Care's stock was under scrutiny, with Lake Street Capital upgrading the stock to a buy rating, while other brokerages maintained a "hold" recommendation.

1.c. Company Highlights

2. Tandem Diabetes Care's Strong 2025 Results and Promising 2026 Outlook

Tandem Diabetes Care achieved a significant milestone in 2025 with over $1 billion in sales, driven by a 12% year-over-year growth in worldwide sales. The company's Q4 sales reached a record $290 million, a 15% year-over-year growth. The U.S. sales grew by 10% to $707 million, while international sales increased by 15% to $308 million. The company's actual EPS loss of -$0.01 beat estimates of -$0.05. The revenue growth was accompanied by a gross margin that is expected to step up to a range of 56% to 57% in 2026.

Publication Date: Feb -23

📋 Highlights
  • $1 Billion Revenue Milestone in 2025: Tandem achieved over $1 billion in sales, with Q4 record sales of $290 million (+15% YoY).<br>
  • Global Sales Growth: U.S. sales rose to $707 million (+10%), while international sales grew to $308 million (+15%) in 2025.<br>
  • PayGo Model Transition: 2026 PayGo adoption in the pharmacy channel will drive 10-11% revenue growth but incur a $70–80 million headwind, with margin expansion to 56–57%.<br>
  • Pharmacy Channel Expansion: 20% of pump shipments will go through the pharmacy channel in 2026, reducing out-of-pocket costs and improving access for 80% of PBM-covered lives.<br>
  • Margin Expansion and EBITDA Leverage: Gross margin to reach 60% by 2026, with adjusted EBITDA leverage of 5–6%, driven by product cost reductions and new technology launches.<br>

Business Model Evolution and Growth Drivers

The company's growth was driven by its modernized commercial organization, new technology, and reshaped business model. Tandem expanded its sales team, updated sales processes, and implemented new systems. The launch of Control-IQ+, its next-generation automated insulin delivery algorithm, and new pump features also contributed to the growth. The company is adopting a pay-as-you-go reimbursement structure in the pharmacy channel in 2026, which is expected to drive market expansion and profitability.

2026 Outlook and Key Highlights

For 2026, Tandem expects worldwide sales to be in the range of $1.065 billion to $1.085 billion, with U.S. sales between $730 million to $745 million and international sales between $335 million to $340 million. The company expects gross margin to expand and adjusted EBITDA to demonstrate leverage. The new pay-as-you-go model is expected to drive growth, with 20% of pumps in 2026 going through the pharmacy channel. The company's guidance for Q1 and the full year in the U.S. shows low double-digit U.S. shipments and mid-teens international underlying growth.

Valuation and Key Metrics

With a P/S Ratio of 1.64 and an EV/EBITDA of -12.37, the market seems to be pricing in a certain level of growth for Tandem Diabetes Care. The company's ROE is -141.98%, and ROIC is -27.83%, indicating that the company is still in a phase of investment. As the company transitions to the pay-as-you-go model and expands its pharmacy channel, it is expected to drive growth and improve profitability.

Growth Prospects and Challenges

Tandem Diabetes Care is confident in its ability to accelerate new pump shipments in 2026, driven by new technology, sales force productivity improvements, and the pharmacy channel. The company expects to see substantial growth in the pharmacy channel, with 10% of customers ordering supplies through the channel this year and 20% of pump shipments going through the pharmacy in 2026. The shift to the pharmacy channel is expected to impact the P&L and sales growth in '27 and '28, with revenue and profitability tailwinds from increased reimbursement on supplies and the opportunity to shift existing customers to the pharmacy channel.

3. NewsRoom

Card image cap

Tandem Diabetes Care, Inc. $TNDM Position Raised by Intech Investment Management LLC

Mar -09

Source: defenseworld.net

Card image cap

Tandem Mobi Now Compatible with Android Smartphones

Mar -04

Source: businesswire.com

Card image cap

Tandem Diabetes Care Conference: Record 58% Margin, “Toby” Tubeless Mobi and Pharmacy Shift Ahead

Mar -03

Source: defenseworld.net

Card image cap

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Average Recommendation of “Hold” by Brokerages

Mar -02

Source: defenseworld.net

Card image cap

Tandem Diabetes Care, Inc. (TNDM) Presents at Citi's 2026 Unplugged MedTech and Life Sciences Access Day Transcript

Feb -26

Source: seekingalpha.com

Card image cap

Tandem Diabetes Care Prices Upsized Private Placement of $265 Million of Convertible Senior Notes Due 2032

Feb -25

Source: businesswire.com

Card image cap

Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Up 9% Following Analyst Upgrade

Feb -24

Source: defenseworld.net

Card image cap

Tandem Diabetes Care: Strong Q4 Execution Amid A PayGo Transition

Feb -23

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.74%)

6. Segments

Supplies and Other

Expected Growth: 8%

Tandem Diabetes Care's Supplies and Other segment growth of 8% is driven by increasing adoption of t:slim X2 insulin pumps, expansion of sales channels, and growing demand for diabetes management solutions. Additionally, the company's focus on customer loyalty and retention programs, as well as strategic partnerships, contribute to the segment's growth.

Pump

Expected Growth: 12%

Tandem Diabetes Care's 12% growth is driven by increasing adoption of its t:slim X2 insulin pump, strong sales of its Basal-IQ technology, and expanding market share in the insulin pump market. Additionally, the company's focus on innovation, customer loyalty, and strategic partnerships contribute to its growth momentum.

Deferral for Tandem Choice Program

Expected Growth: 6%

The 6% growth of Deferral for Tandem Choice Program is driven by increasing adoption of insulin pumps, rising diabetes prevalence, and growing demand for user-friendly diabetes management systems. Additionally, Tandem Diabetes Care's strategic partnerships, expanding product portfolio, and favorable reimbursement policies contribute to the growth.

Pump Rebate

Expected Growth: 4%

Tandem Diabetes Care, Inc.'s Pump Rebate growth is driven by increasing adoption of insulin pumps, rising diabetes prevalence, and growing demand for convenient and discreet diabetes management solutions. Additionally, the company's innovative products, such as the t:slim X2 insulin pump, and strategic partnerships are contributing to the growth.

7. Detailed Products

t:slim X2

A touchscreen insulin pump that is small, durable, and waterproof, with a rechargeable battery that can last up to 7 days.

t:flex

A high-capacity insulin pump that holds up to 480 units of insulin, with a rechargeable battery that can last up to 15 days.

Basal-IQ Technology

A predictive low glucose suspend feature that can automatically suspend insulin delivery when glucose levels are predicted to go low.

Control-IQ Technology

An advanced hybrid closed-loop system that automatically adjusts insulin delivery based on glucose levels, trends, and other factors.

t:connect Mobile App

A mobile app that allows users to view their diabetes data, track their glucose levels, and receive notifications and alerts.

t:connect Web Application

A web-based platform that allows users to view their diabetes data, track their glucose levels, and receive notifications and alerts.

8. Tandem Diabetes Care, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Tandem Diabetes Care, Inc. faces moderate threat from substitutes, as patients may opt for alternative treatments or insulin pumps from competitors.

Bargaining Power Of Customers

Customers have limited bargaining power due to the specialized nature of Tandem Diabetes Care, Inc.'s products and the lack of substitutes.

Bargaining Power Of Suppliers

Suppliers of components and materials have moderate bargaining power, as Tandem Diabetes Care, Inc. relies on a few key suppliers for critical components.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry, including regulatory hurdles and the need for significant investments in research and development.

Intensity Of Rivalry

The insulin pump market is highly competitive, with several established players competing for market share, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 57.00%
Debt Cost 3.95%
Equity Weight 43.00%
Equity Cost 9.43%
WACC 6.30%
Leverage 132.53%

11. Quality Control: Tandem Diabetes Care, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
TransMedics

A-Score: 4.8/10

Value: 1.0

Growth: 9.0

Quality: 6.7

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Globus Medical

A-Score: 4.4/10

Value: 3.0

Growth: 6.3

Quality: 7.2

Yield: 0.0

Momentum: 6.0

Volatility: 3.7

1-Year Total Return ->

View Full Report
Stock-Card
ShockWave Medical

A-Score: 4.2/10

Value: 0.0

Growth: 9.7

Quality: 7.1

Yield: 0.0

Momentum: 6.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Bruker

A-Score: 3.5/10

Value: 5.9

Growth: 5.2

Quality: 2.9

Yield: 0.0

Momentum: 3.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Integer

A-Score: 3.2/10

Value: 4.5

Growth: 5.1

Quality: 4.7

Yield: 0.0

Momentum: 0.5

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Tandem Diabetes Care

A-Score: 3.1/10

Value: 7.2

Growth: 3.6

Quality: 3.6

Yield: 0.0

Momentum: 2.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

21.88$

Current Price

21.88$

Potential

-0.00%

Expected Cash-Flows